Sugi Predict

Sugi Predict / Compounds / SCHEMBL22804240

SCHEMBL22804240

SCHEMBL22804240

COc1ccc([N+](=O)[O-])c(Br)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.49
▸ TDP1 Q9NUW8 3/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ ERN1 O75460 1/20 0.44
▸ LMNA P02545 3/20 0.43
▸ ABCB1 P08183 1/20 0.43
▸ ABCC1 P33527 1/20 0.43
▸ MAPT P10636 3/20 0.43
▸ POLB P06746 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.42
▸ CTDSP1 Q9GZU7 1/20 0.42
▸ GPR35 Q9HC97 1/20 0.41
▸ GAA P10253 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ AMY1A P0DUB6 1/20 0.41
▸ EGFR P00533 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ ALOX15 P16050 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68284 0.84 TDP1 (0.53) ALDH1A1TDP1L3MBTL1ERN1LMNA
SCHEMBL11559751 0.81 ALDH1A1 (0.50) ALDH1A1TDP1L3MBTL1LMNAMAPT
SCHEMBL9023924 0.81 ALDH1A1 (0.50) ALDH1A1TDP1L3MBTL1LMNAMAPT
SCHEMBL28991054 0.81 ALDH1A1 (0.50) ALDH1A1TDP1L3MBTL1LMNAMAPT
SCHEMBL8349793 0.81 ALDH1A1 (0.50) ALDH1A1TDP1L3MBTL1LMNAMAPT
SCHEMBL632800 0.79 ALDH1A1 (0.49) ALDH1A1TDP1L3MBTL1LMNAMAPT
SCHEMBL9072461 0.77 ALDH1A1 (0.50) ALDH1A1TDP1L3MBTL1LMNAMAPT
SCHEMBL7696511 0.77 TDP1 (0.50) ALDH1A1TDP1L3MBTL1LMNAMAPT
SCHEMBL5322745 0.77 ALDH1A1 (0.50) ALDH1A1TDP1L3MBTL1LMNAMAPT
SCHEMBL10501311 0.77 ERN1 (0.57) ALDH1A1TDP1ERN1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116217566-B Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof 杭州和正医药有限公司 2025-05-23 — — CN disclosed
CN-119431212-A Synthesis method of 7-bromo-5, 6-bis (benzyloxy) benzopyrrole and derivative dimer thereof 中国科学院生物物理研究所 2025-02-14 — — CN disclosed
US-20250034135-A1 ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF Hangzhou Healzen Therapeutics Co., Ltd. (CN) 2025-01-30 — — US disclosed
EP-4442685-A1 ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF Hangzhou HealZen Therapeutics Co., Ltd. (CN) 2024-10-09 — — EP disclosed
CN-117794923-A Benzodioxane compound, and preparation method and application thereof 南京红云生物科技有限公司 2024-03-29 — — CN disclosed
CN-112469713-B Aryl phosphorus oxide derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2023-09-01 — — CN disclosed
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY SPERMATECH AS (NO) 2023-08-24 — — US disclosed
WO-2023104043-A1 ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF 杭州和正医药有限公司 2023-06-15 — — WO disclosed
CN-116217566-A Anti-apoptosis protein BCL-2 inhibitor, pharmaceutical composition and application thereof 杭州和正医药有限公司 2023-06-06 — — CN disclosed
CN-116234556-A Crystal form of aryl phosphorus oxide derivative free alkali and preparation method and application thereof 江苏豪森药业集团有限公司 2023-06-06 — — CN disclosed
WO-2023011610-A1 BENZODIOXANE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 南京红云生物科技有限公司 2023-02-09 — — WO disclosed
WO-2022127807-A1 CRYSTAL FORM OF ARYL PHOSPHORUS OXIDE DERIVATIVE FREE BASE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 江苏豪森药业集团有限公司 2022-06-23 — — WO disclosed
WO-2022127807-A1 CRYSTAL FORM OF ARYL PHOSPHORUS OXIDE DERIVATIVE FREE BASE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 江苏豪森药业集团有限公司 2022-06-23 — — WO disclosed
CN-114644654-A Oxidized aryl phosphorus derivative, acid salt or crystal form thereof, and preparation method and application thereof 上海翰森生物医药科技有限公司 2022-06-21 — — CN disclosed
CN-112469713-A Aryl phosphorus oxide derivative inhibitor, preparation method and application thereof 江苏豪森药业集团有限公司 2021-03-09 — — CN disclosed
WO-2020253860-A1 ARYL PHOSPHORUS OXIDE DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2020-12-24 — — WO disclosed
WO-2020253860-A1 ARYL PHOSPHORUS OXIDE DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2020-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230263155-A1 5-(1H-INDOL-3-YL)-OXAZOLE, -OXADIAZOLE AND -FURAN DERIVATIVES AS ENHANCERS OF SPERM MOTILITY NR5A1, NR1I3, NR5A2 ALDH1A1 1219/4885TDP1 2064/4885L3MBTL1 2907/4885
US-20250034135-A1 ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF BCL2, BAX, BCL2L1 ALDH1A1 4614/4885TDP1 2645/4885L3MBTL1 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.